Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities are to foster better access to generic, biosimilar and value added medicines for patients, to stimulate competition in off-patent medicine markets and support sustainable pricing policies, to promote high regulatory standards while ensuring continued supply and access to medicines and to develop a coherent EU industrial strategy to support dynamic and competitive generic, biosimilar and value added medicines industries in Europe. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher in Italy (EUI), France (Nice) and Canada (Windsor).
Previously attended as speaker on the following Portfolio conference: